This is the authors' abstract. We don't add key points for this paper.
Cancers rising prevalence demands novel treatments. Chimeric Antigen Receptor T-cell (CAR-T) therapy emerges as a transformative option. Conventional cancer treatments of-ten lack efficacy and carry severe side effects. This study focuses on enhancing CAR-T therapy against solid tumors. Strategies include lowering CAR affinity for antigens and in-tegrating PD-1&CD-28 chimeric antigen complexes. While CAR-T therapy excels against hematological malignancies, challenges remain, such as immune checkpoint upregulation and potential toxicity. The research aims to optimize CAR-T therapys efficacy through innovative modifications. Alternative strategies like multi-targeted CARs and combina-tions with immune checkpoint inhibitors are explored. Overall, this study advances can-cer therapy by addressing CAR-T therapys limitations and proposing complementary strategies for improved personalized treatments.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: